WilmerHale Advises Vtesse in $17M Series A Funding

  • 7.26.2016

Vtesse, Inc., a company committed to developing drugs that will benefit patients with extremely rare, life-threatening diseases, secured $17 million in Series A funding in support of its global, pivotal clinical trial of VTS-270 for Niemann-Pick Type C1 disease (NPC).

The company's ongoing Phase 2b/3 prospective, randomized, double-blind, sham-controlled trial of VTS-270 is being conducted in patients affected by NPC disease. It is a three-part efficacy and safety trial of VTS-270, administered by the intrathecal route (IT) every two weeks, with planned enrollment of approximately 51 patients.

Partner Gary Schall counseled Vtesse.

For more information read Vtesse's press release.

See other News & Publications related to:

See related industries:

Life Sciences